<SEC-DOCUMENT>0001171843-15-005654.txt : 20151022
<SEC-HEADER>0001171843-15-005654.hdr.sgml : 20151022
<ACCEPTANCE-DATETIME>20151022094936
ACCESSION NUMBER:		0001171843-15-005654
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20151022
FILED AS OF DATE:		20151022
DATE AS OF CHANGE:		20151022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		151169275

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 6-K FILING DOCUMENT
<TEXT>
<html lang="en-US">

	<head>
		<title>Form 6-K Filing</title>
	</head>

	<body bgcolor="#ffffff">
		<div align="center">
			<b><font size="4">UNITED STATES<br>
					SECURITIES AND EXCHANGE COMMISSION</font><br>
				Washington, D.C. 20549</b>
			<p><b><font size="4">FORM 6-K</font></b></p>
			<p><b>Report of Foreign Private Issuer<br>
					Pursuant to Rule 13a-16 or 15d-16<br>
					of the Securities Exchange Act of 1934 </b></p>
			<p><font size="2">For the month of <b>October 2015</b>.</font><br>
				<font size="2">Commission File No.:001-35773</font></p>
			<p><font size="4"><b>REDHILL BIOPHARMA LTD.</b></font><br>
				<font size="2">(Translation of registrant's name into English)</font></p>
			<p><b>21 Ha'arba'a Street, Tel Aviv, 64739, Israel</b><br>
				<font size="2">(Address of principal executive office)</font></p>
			</p></div>
		<p><font size="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></p>
		<p align="center">Form 20-F [ x] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F [ &nbsp;]</font></p>
		<p><font size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></p>
		<p><font size="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></p>
		<!--<p><font size="2">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ &nbsp;&nbsp;] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No [  x ]</font></p>
		<p><font size="2">If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>.</font></p>-->

		<p><font size="2"><p>
	Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: <i>&quot;</i><i>RedHill Biopharma to Present at Gelbart-Kahana Biomed Conference on October 25, 2015&quot;.</i></p>
<p>
	 </p>
<p>
	This Form 6-K is incorporated by reference into the Company&#39;s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286) and its Registration Statement on Form F-3 filed with the Securities and Exchange Commission on January 23, 2014 (Registration No. 333-193503).</p>
</font></p>
		<div align="center">
			<hr noshade="1">
			<b><font size="2">SIGNATURES</font></b></div>
		<p><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%">&nbsp;</td>
				<td width="6%">&nbsp;</td>
				<td width="47%">REDHILL BIOPHARMA LTD.<br>
					<font size="2">(Registrant)</font><br>
					<br>
				</td>
			</tr>
			<tr valign="top">
				<td width="47%"><font size="2">Date: October 22, 2015</font></td>
				<td width="6%">&nbsp;</td>
				<td width="47%"><font size="2">By: <u>/s/ DROR BEN-ASHER</u><br>
					Dror Ben-Asher<br>
					Chief Executive Officer</font></td>
			</tr>
		</table>
		<div align="center">
			<p></p>
		</div>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>RedHill Biopharma to Present at Gelbart-Kahana Biomed Conference on October 25, 2015</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">RedHill Biopharma to Present at Gelbart-Kahana Biomed Conference on October 25, 2015</h3><p>TEL-AVIV, Israel, Oct. 22, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Ori Shilo, RedHill's Deputy CEO Finance and Operations, will present at the Gelbart-Kahana Biomed Conference on Sunday, October 25, 2015, at the Tel-Aviv Stock Exchange, Israel.</p><p>
	To participate in the conference please contact Gelbat-Kahana by email at: erang@gk-biz.com, or by telephone: +972-(0)3-6070-59.</p><p>
	A copy of the presentation to be made by Mr. Shilo is available on the Company's website and may be viewed at the following web address: http://ir.redhillbio.com/</p><p>
	<strong>About RedHill Biopharma Ltd.:</strong></p><p>
	RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company primarily focused on the development of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. RedHill's current pipeline of proprietary products includes: (i) <strong>RHB-105</strong> <strong>-</strong> an oral combination therapy for the treatment of <i>Helicobacter pylori</i> infection with successful top-line results from a first Phase III study; (ii) <strong>RHB-104</strong> <strong>-</strong> an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study; (iii) <strong>BEKINDA<sup>&#8482;</sup></strong><strong> (RHB-102)</strong> <strong>-</strong> a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted in December 2014; (iv) <strong>RHB-106</strong> <strong>-</strong> an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) <strong>YELIVA<sup>&#8482;</sup> (ABC294640)</strong> <strong>-</strong> an orally-administered first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications with a Phase I/II study initiated for refractory/relapsed diffuse large B-cell lymphoma (DLBCL); (vi) <strong>MESUPRON<sup>&#174;</sup> - </strong>a Phase II-stage first-in-class uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) <strong>RP101</strong> <strong>-</strong> currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii)<strong> RIZAPORT<sup>&#8482;</sup> (RHB-103)</strong> <strong>-</strong> an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussion with the FDA and a European marketing application submitted in October 2014; and (ix) <strong>RHB-101</strong> <strong>-</strong> a once-daily oral pill formulation of the cardio drug carvedilol.</p><p>
	<i>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to establish and maintain corporate collaborations; (vi) the interpretation of the properties and characteristics of the Company's therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (vii) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (ix) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (x) estimates of the Company's expenses, future revenues capital requirements and the Company's needs for additional financing; (xi) competitive companies and technologies within the Company's industry; and (xii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC </i><i>on February 26, 2015. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.</i></p><pre>CONTACT: Company contact:
         Adi Frish
         Senior VP Business Development &amp;
         Licensing
         RedHill Biopharma
         +972-54-6543-112
         adi@redhillbio.com

         IR contact (U.S.):
         Marcy Nanus
         Senior Vice President
         The Trout Group
         +1-646-378-2927
         Mnanus@troutgroup.com</pre></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
